Baseline and Treatment Characteristics
| Characteristic | Data |
|---|---|
| Patients | 272 |
| Procedures | 317 |
| Sex | |
| Male | 170 (62.5%) |
| Female | 102 (37.5%) |
| Mean age | 64.56 (17–90) |
| Sphere type | |
| Glass | 200 (63%) |
| Resin | 117 (37%) |
| Median administered activity (MBq) | |
| Glass | 2,278 (277–9,636) |
| Resin | 1,877 (516–3,245) |
| Mean number of 90Y sessions | 1.17 (1–5) |
| Tumor types | |
| Colorectal cancer | 104 (38%) |
| HCC | 68 (25%) |
| Neuroendocrine tumor | 45 (16%) |
| Cholangiocellular carcinoma | 21 (8%) |
| Others | 34 (13%) |
| Thrombus | |
| Segmental right portal vein | 9 |
| Lobar left portal vein | 4 |
| Segmental right portal vein plus lobar left portal vein | 1 |
| Tumor thrombosis, main portal vein | 2 |
| Tumor thrombosis, right hepatic vein | 1 |
| Portal hypertension | 33 |
| LSFMAA (%) | |
| Mean | 5.73 (0.49–50.44) |
| Median | 3.87 (4.60) |
| Number of cases > 20% | 11 |
| LSFY-90 (%) | |
| Mean | 5.90 (0.27–39.02) |
| Median | 4.13 (5.28) |
| Number of cases > 20% | 7 |
| 99mTc-based prediction of LMD (Gy) | |
| Mean | 6.93 (0.17–89.03) |
| Median | 3.52 (6.48) |
| Number of cases > 30 Gy | 14 |
| 90Y PET–based left lung dose (Gy) | |
| Mean | 1.59 (0.02–22.14) |
| Median | 0.95 (1.16) |
| Number of cases > 12 Gy | 3 |
| Median total lung volume (mL) | 1,713 (392–7,851) |
| Median left lung volume (mL) | 733 (80–3,792) |
Qualitative data are number; continuous data are mean and range or median and interquartile range.